Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Leases (2016 - 2025)

Enanta Pharmaceuticals filings provide 9 years of Current Leases readings, the most recent being $3.3 million for Q4 2025.

  • On a quarterly basis, Current Leases rose 226.74% to $3.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.3 million, a 226.74% increase, with the full-year FY2025 number at $3.1 million, up 106.43% from a year prior.
  • Current Leases hit $3.3 million in Q4 2025 for Enanta Pharmaceuticals, up from $3.1 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $5.4 million in Q2 2023 to a low of $1.0 million in Q4 2024.
  • Median Current Leases over the past 5 years was $3.4 million (2021), compared with a mean of $3.5 million.
  • Biggest five-year swings in Current Leases: crashed 79.74% in 2024 and later soared 226.74% in 2025.
  • Enanta Pharmaceuticals' Current Leases stood at $3.5 million in 2021, then increased by 0.49% to $3.5 million in 2022, then skyrocketed by 42.46% to $5.0 million in 2023, then crashed by 79.74% to $1.0 million in 2024, then soared by 226.74% to $3.3 million in 2025.
  • The last three reported values for Current Leases were $3.3 million (Q4 2025), $3.1 million (Q3 2025), and $2.4 million (Q2 2025) per Business Quant data.